← Leaderboards
Sara Lustigman
New York Blood Center
$21,771,096
Attributed
$31,256,273
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,256,273 · 18
By mechanism
R01$19,629,688 · 6
U01$6,780,493 · 2
R56$2,000,120 · 3
R21$1,871,539 · 5
P50$868,755 · 1
R03$105,678 · 1
Top collaborators
- James W Janetka7 shared
- Makedonka Mitreva7 shared
- Maria Elena Bottazzi5 shared
- Hao Shen5 shared
- Judy Sakanari4 shared
- Shibo Jiang3 shared
- Lanying Du2 shared
- Elodie Ghedin2 shared
Most similar at New York Blood Center
Same institution · by research overlap
- Cheryl Ann Lobo$8,181,413
- Shibo Jiang$8,062,102
- Lanying Du$16,789,459
Others in their field
Top investigators on “Parasites”
- Stephen Lev Hoffman · Sanaria, Inc.$58,168,134
- L David Sibley · Washington University$47,818,729
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,087,946
- Wilhelmus G. J. Hol · University Of Washington$32,390,237
- Philip Jon Rosenthal · University Of California San Francisco$31,794,731
- Daniel F. Hoft · Saint Louis University$31,137,771
Research focus
ParasitesOnchocerca VolvulusAdultProteinsResponseVaccinesOnchocerciasisImmune ResponseIn VivoNematodaPathway InteractionsBaseCellsVaccinationAreaAdjuvantInfectionProgramsIn VitroPharmaceutical PreparationsAntigensInnovationIvermectinAnimal Model
Grant awards (59)
Innovative therapeutic strategies to support elimination of river blindness$805,959
R01 · FY2025 · AI
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination$719,415
U01 · FY2025 · AI · contact PI
Effects of Exogenous Hormone Treatment on Vaccine Responses$267,121
R21 · FY2025 · AI · contact PI
Innovative therapeutic strategies to support elimination of river blindness$805,271
R01 · FY2024 · AI
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination$719,415
U01 · FY2024 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$410,000
R01 · FY2024 · EY
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination$134,320
U01 · FY2024 · AI · contact PI
Innovative therapeutic strategies to support elimination of river blindness$834,159
R01 · FY2023 · AI
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination$719,415
U01 · FY2023 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$410,000
R01 · FY2023 · EY
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination$719,415
U01 · FY2022 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$397,700
R01 · FY2022 · EY
The development of a recombinant vaccine against human onchocerciasis$775,846
R01 · FY2021 · AI · contact PI
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination$737,115
U01 · FY2021 · AI · contact PI
Integrative approach for accelerating filarial worm drug discovery to treat river blindness$409,999
R01 · FY2021 · EY
Activating autophagy in filarial worms to identify novel macrofilaricides$258,750
R21 · FY2021 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$684,875
R01 · FY2020 · AI · contact PI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$526,550
U01 · FY2020 · AI · contact PI
Activating autophagy in filarial worms to identify novel macrofilaricides$237,875
R21 · FY2020 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$683,255
R01 · FY2019 · AI · contact PI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$555,526
U01 · FY2019 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$694,825
R01 · FY2018 · AI · contact PI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$569,174
U01 · FY2018 · AI · contact PI
Innovative 3-D in vitro culturing systems for filarial worms$173,532
R21 · FY2018 · AI · contact PI
Development of a novel adjuvant for vaccine sparing$1,248,398
R01 · FY2017 · AI · contact PI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$784,531
U01 · FY2017 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$770,747
R01 · FY2017 · AI · contact PI
Innovative 3-D in vitro culturing systems for filarial worms$236,332
R21 · FY2017 · AI · contact PI
Development of a novel adjuvant for vaccine sparing$1,250,865
R01 · FY2016 · AI · contact PI
Functional interplay between Brugia and its Wolbachia symbiont$770,293
R56 · FY2016 · AI · contact PI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$595,617
U01 · FY2016 · AI · contact PI
Development of a novel adjuvant for vaccine sparing$1,197,649
R01 · FY2015 · AI · contact PI
Development of a novel adjuvant for vaccine sparing$1,203,147
R01 · FY2014 · AI · contact PI
Development of a novel adjuvant for vaccine sparing$1,393,822
R01 · FY2013 · AI · contact PI
Molecular mechanisms of filarial endosymbiosis$613,492
R56 · FY2013 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$603,776
R01 · FY2013 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$653,219
R01 · FY2012 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$679,506
R01 · FY2011 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$714,313
R01 · FY2010 · AI · contact PI
The development of a recombinant vaccine against human onchocerciasis$708,326
R01 · FY2009 · AI · contact PI
Malaria in Brazil: RBC variants & parasite invasion$315,570
R56 · FY2009 · AI · contact PI
Malaria in Brazil: RBC variants & parasite invasion$300,765
R56 · FY2008 · AI · contact PI
Malaria Invasion Via Glycophorin B in Brazilian Isolates$31,252
R03 · FY2007 · TW · contact PI
A Helminth-Derived Immune Potentiator for Biodefense$197,500
R21 · FY2006 · AI · contact PI
Malaria Invasion Via Glycophorin B in Brazilian Isolates$32,186
R03 · FY2006 · TW · contact PI
Malaria invasion: Red cell receptor /ligand interactions$440,797
P50 · FY2005 · HL
Cysteine Proteases &Inhibitors in Nematode Development$309,929
R01 · FY2005 · AI
A Helminth-Derived Immune Potentiator for Biodefense$237,000
R21 · FY2005 · AI
Malaria Invasion Via Glycophorin B in Brazilian Isolates$42,240
R03 · FY2005 · TW
Malaria invasion: Red cell receptor /ligand interactions$427,958
P50 · FY2004 · HL
Cysteine Proteases &Inhibitors in Nematode Development$309,929
R01 · FY2004 · AI
Cysteine Proteases &Inhibitors in Nematode Development$309,929
R01 · FY2003 · AI
Cysteine Proteases &Inhibitors in Nematode Development$309,929
R01 · FY2002 · AI
Malaria invasion: Red cell receptor /ligand interactions$0
P50 · FY2002 · HL
PROTECTIVE IMMUNITY IN HUMANS AGAINST O VOLVULUS LARVAE$389,602
R01 · FY2001 · AI
Cysteine Proteases &Inhibitors in Nematode Development$281,539
R01 · FY2001 · AI
Malaria invasion: Red cell receptor /ligand interactions$0
P50 · FY2001 · HL
PROTECTIVE IMMUNITY IN HUMANS AGAINST O VOLVULUS LARVAE$383,174
R01 · FY2000 · AI
CYSTEINE PROTEASES &INHIBITORS IN NEMATODE DEVELOPMENT$263,429
R21 · FY2000 · AI